孟鲁斯特治疗支气管哮喘的临床观察

摘要

Objective: To observe the long-term therapeutic effect of Montelukast on bronchial asthma.Methods: Forty patients with bronchial asthma were enrolled and divided into treatment group and control group randomly.The patients in control group were treated with inhaled corticosteroid (ICS) (10 mg/d) and long acting p2-agonist (LABA), and those in treatment group were added Montelukast.Both of the groups were inhaled short-acting p2-agonists and given oxygen therapy.Results: The effective rate of treatment group was higher than that of control group (90.0％ vs 85.0％, P＜0.05).Conclusion: Montelukast is an effective and safe treatment method to bronchial asthma and worthy to clinical application.%目的:观察孟鲁斯特对支气管哮喘的疗效.方法:将40例支气管哮喘患者随机分为治疗组和对照组,各40例,治疗组在对照组的基础上应用孟鲁斯特10 mg/d,对照组予吸入糖皮质激素(ICS)布地奈德喷雾剂和长效β2受体激动剂(LABA)福莫特罗喷雾剂,急性严重发作时加用速效吸入β2受体激动剂和吸氧治疗.比较两组哮喘缓解情况和发作的频率及总有效率.结果:治疗组总有效率为90.0%(36/40例)高于对照组85.0%(34/40例),差异有统计学意义(P<0.05).结论:孟鲁斯特对支气管哮喘的疗效显著,安全性好,值得推广应用.